Latest News & Features
Americas
Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology. 19 October 2018
Americas
Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more. 19 October 2018
Big Pharma
The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). 18 October 2018
Americas
The US Food and Drug Administration has announced that it has partnered with the US Department of Homeland Security as part of the FDA’s aim to strengthen cybersecurity in healthcare. 18 October 2018
Americas
The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed. 17 October 2018
Americas
Nestlé Skin Health and Palette Life Sciences have entered into a global licensing agreement intended to improve outcomes for patients with urological and colorectal disorders. 17 October 2018
Americas
After spending four years at Hughes Hubbard & Reed, Stephen Rabinowitz has joined Dechert’s New York office as a partner. 17 October 2018
Big Pharma
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports. 17 October 2018
Big Pharma
The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK. 16 October 2018
Biotechnology
ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon. 16 October 2018